Dr Marc Bickle

Marc Bickle heads the Technology Development Studio (TDS) of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. The TDS is an open access screening facility specialised in high content screening of RNAi and chemical libraries. The TDS uses open source software to allow its clients to recreate the analytical workflows in their own laboratories. There is therefore a strong need for its client to learn how to use these powerful analytical tools and hands on courses are consequently offered. Marc Bickle obtained his PhD at the Biozentrum in Basel, Switzerland, studying the immunosuppressive drug Rapamycin helping elucidate its mode of action. He then went to the LMB in Cambridge, UK, to study the genetics of behavior in C. elegans. He then participated in the creation of Aptanomics, a drug discovery Biotech in Lyon, France, where he set up several yeast two hybrid screening systems.